Cadrenal Therapeutics, Inc. (CVKD) Institutional Ownership

Ownership Summary

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) currently has 5 active institutional owners and shareholders as of today (December 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• The percentage of Cadrenal Therapeutics owned by institutions changed from 6.4% in September 2025 to 3.1% in December 2025, marking a slight down trend.
• The company experienced a 1.26% quarterly change in institutional shares held, alongside a decrease of 50.00% in total owners annually.
• During the quarter, 1 institutions bought more Cadrenal Therapeutics shares, 1 sold shares, and 3 of the 5 total investors held their position steady.
• The total number of shares held by institutions in Cadrenal Therapeutics increased to 55.02K as of December 2025, a net change of up by 682 shares quarter on quarter, and up 40.19K shares year over year.
• VANGUARD GROUP INC continues to be the largest institutional holder of Cadrenal Therapeutics as of December 31, 2025, with a position of 53.91K shares, representing 3.00% of the company's outstanding stock.
• Among the most significant buyers of Cadrenal Therapeutics during December 2025 were UBS Group AG (1.01K).
• Leading sellers of Cadrenal Therapeutics stock in December 2025 included VANGUARD GROUP INC (327).
• The top 5 institutional holders of Cadrenal Therapeutics for the quarter ending December 2025 included VANGUARD GROUP INC (53.91K), UBS Group AG (1.04K), Archer Investment Corp (35), Farther Finance Advisors, LLC (25), CALDWELL SUTTER CAPITAL, INC. (5).